A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

October 20, 2022

Study Completion Date

October 20, 2022

Conditions
Castration-resistant Prostate CancerNon-small Cell Lung CancerColorectal Cancer
Interventions
DRUG

SM08502

SM08502 to be administered orally.

DRUG

Abiraterone

Abiraterone to be administered orally.

DRUG

Prednisone

Prednisone to be administered orally.

DRUG

Docetaxel

Docetaxel to be administered intravenously.

DRUG

FOLFIRI Protocol

FOLFIRI Protocol to be administered intravenously.

DRUG

Panitumumab

Panitumumab to be administered intravenously.

Trial Locations (20)

2010

Saint Vincent's Hospital, Darlinghurst

2050

Chris O'Brien Lifehouse, Camperdown

4215

Icon Cancer Care-South Brisbane, South Brisbane

5011

The Queen Elizabeth Hospital (TQEH), Woodville South

20176

Virginia Cancer Specialists, PC, Fairfax

24014

Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Roanoke

37212

Vanderbilt University, Nashville

45219

The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, LLC, Cincinnati

49546

START Midwest, Grand Rapids

76104

Texas Oncology, Fort Worth

78217

Texas Oncology-San Antonio Northeast, San Antonio

78229

UT Health San Antonio - Mays Cancer Center - Institute for Drug Development, San Antonio

80045

University of Colorado, Aurora

84119

START Mountain Region, West Valley City

85719-1478

The University of Arizona Cancer Center (UACC) - North Campus, Tucson

80045-2571

University of Colorado, Anschutz, Aurora

04074-7172

Maine Center for Cancer Medicine, Scarborough

10021-0005

Memorial Sloan-Kettering Cancer Center, New York

27710-2000

Duke Cancer Institute (DCI) - Duke Cancer Center, Durham

98109-1023

Seattle Cancer Care Alliance (SCCA), Seattle

Sponsors
All Listed Sponsors
lead

Biosplice Therapeutics, Inc.

INDUSTRY